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Abstract
Antiestrogens are currently used for treating breast cancer
patients who have estrogen receptor–positive tumors.
However, patients with advanced disease will eventually
develop resistance to the drugs. Therefore, compounds
effective on antiestrogen-resistant tumors will be of great
importance for future breast cancer treatment. In this
study, we have investigated the effect of the chemother-
apeutic compound cisplatin using a panel of antiestrogen-
resistant breast cancer cell lines established from the
human breast cancer cell line MCF-7. We show that the
antiestrogen-resistant cells are significantly more sensitive
to cisplatin-induced cell death than antiestrogen-sensitive
MCF-7 cells and we show that cisplatin induces cell death
by activating both the caspase and lysosomal death
pathways. The antiestrogen-resistant cell lines express
lower levels of antiapoptotic Bcl-2 protein compared with
parental MCF-7 cells. Our data show that Bcl-2 can
protect antiestrogen-resistant breast cancer cells from
cisplatin-induced cell death, indicating that the reduced
expression of Bcl-2 in the antiestrogen-resistant cells plays
a role in sensitizing the cells to cisplatin treatment. [Mol
Cancer Ther 2007;6(6):1869–76]
Introduction
The use of antiestrogens, such as tamoxifen, as therapy for
estrogen-responsive breast cancers has been used for
almost three decades. However, a major clinical problem
with the use of antiestrogens is that most patients with
advanced disease eventually develop resistance to the
compounds. The exact molecular mechanisms behind
development of antiestrogen resistance are still not clear
although several mechanisms have been proposed, includ-
ing loss of estrogen receptor-a expression, posttranslational
modifications of the estrogen receptor, and changes in
signal transduction (1). In the case of tamoxifen, the partial
agonistic properties of the compound have been suggested
to play a role in development of resistance to tamoxifen
treatment (2). ICI 182,780 (Faslodex; refs. 3, 4) and ICI
164,384 (5) are pure antagonists of estrogen receptor, but
these compounds also give rise to outgrowth of resistant
cancer cells both in vitro (6–8) and in vivo (9). More and
more evidence now points to altered signal transduction as
a way for the cancer cells to shift from estrogen receptor–
mediated signaling to other cellular pathways [e.g., path-
ways involving the epidermal growth factor receptor (10)
and the phosphatidylinositol 3-kinase-Akt pathway (11)].
Therefore, taking advantage of these changed properties
of the resistant cells could lead to new strategies for
preventing and treating antiestrogen resistance in breast
cancer patients.
Cisplatin (cis-diamminedichloroplatinum II) is a plati-
num compound used for treatment of a variety of cancers.
Cisplatin is active in breast carcinoma given alone (12)
or in combination with other chemotherapeutic drugs
(13–15). In women with HER2-positive metastatic breast
cancer, treatment with cisplatin, or the related carboplatin,
in combination with taxanes and trastuzumab (Herceptin)
shows promising results (16, 17). Cisplatin induces intra-
strand and interstrand cross-links in DNA, resulting in
DNA adducts, which is followed by induction of cell
death. Cisplatin activates caspases through different
signaling pathways, including stabilization of tumor
suppressor protein p53 and release of cytochrome c from
mitochondria (18). Evidence of alternative death programs
has emerged during the past few years, where it has
become clear that chemotherapeutic compounds, includ-
ing cisplatin, also can trigger, e.g., lysosomal membrane
permeabilization, resulting in release of lysosomal proteins
to the cytosol (19–21). Lysosomal proteases, such as cys-
teine cathepsin B and L, can induce caspase-independent
programmed cell death (22) or mitochondrial membrane
permeabilization (23), thereby enhancing the caspase-
mediated pathway.
Because it was unknown how the response of anti-
estrogen-resistant cells would be toward cisplatin treat-
ment, our strategy was to compare the cisplatin sensitivity
of MCF-7 human breast cancer cells with MCF-7–derived
antiestrogen-resistant cell lines. We found clear evidence
that acquired antiestrogen resistance sensitized the cells to
cisplatin treatment, and we discovered that cisplatin
induced increased cell death, mediated by both caspases
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and lysosomal proteases. Furthermore, we could show that
down-regulation of Bcl-2, one of the key regulators of
mitochondrial-mediated cell death, was involved in this
sensitization. These results suggest that low doses of
cisplatin given in combination with antiestrogens or given
as second-line or third-line therapy to patients who have
relapsed from endocrine therapy might be a way to
overcome or postpone antiestrogen resistance.
Materials andMethods
Cell Cultures
The MCF-7 cell line was originally obtained from the
Breast Cancer Task Force Cell Culture Bank (Mason
Research Institute, Worcester, MA) and adapted to growth
at low serum concentrations (24). Antiestrogen-resistant
cell lines MCF-7/TAMR-1, MCF-7/182R-1, MCF-7/182R-6,
MCF-7/182R-7, MCF-7/182R-9, MCF-7/164R-4, MCF-7/
164R-5, and MCF-7/164R-7 were established as previously
described (6, 25, 26). MCF-7 cells were propagated in
growth medium consisting of phenol red–free DMEM/F12
(1:1; Life Technologies, Invitrogen) supplemented with 1%
FCS (Life Technologies, Invitrogen), 2.5 mmol/L L-gluta-
mine (Life Technologies, Invitrogen), and 6 ng/mL insulin
(Novo-Nordisk). Growth medium was supplemented with
1 Amol/L tamoxifen (Sigma-Aldrich) for growth of tamox-
ifen-resistant cell lines and with 100 nmol/L ICI 182,780
(Tocris Cookson) for growth of ICI 182,780– and ICI
164,384–resistant cell lines. All cell lines were maintained
at 37jC in humidified air containing 5% CO2.
Treatments and Determination of Cell Number
Cells were seeded 2 days before treatment. At the onset of
treatment, growth medium was changed to medium
containing 10 to 60 Amol/L cisplatin (Sigma-Aldrich) or
cisplatin in combination with either 5 Amol/L z-Val-Ala-DL-
Asp-fluoromethylketone (zVAD-fmk; Bachem) for inhibi-
tion of caspases or 85 Amol/L z-Phe-Ala-fmk (zFA-fmk; MP
Biomedicals) for inhibition of cathepsins. Cells were treated
for 12 to 48 h depending on the experiment. For deter-
mination of cytotoxicity of cisplatin, cells were treated for
24 h and the number of surviving cells attached to the
plastic surface of the multiwells was evaluated by a crystal
violet colorimetric assay (27).
Western Blot Analysis
Cells for Western blot analysis were harvested and
protein extracts were made in radioimmunoprecipitation
assay buffer as described before (11). Determination
of protein concentration was done using the Bio-Rad pro-
tein assay (Bio-Rad Laboratories) and bovine serum albu-
min as standard. Proteins were separated by SDS-PAGE
and transferred to polyvinylidene difluoride membranes
by electroblotting. Membranes were blocked with PBS
containing 0.2% casein and 0.1% Tween 20. Immunostain-
ing was done with primary antibodies directed against
Bcl-2 (1:200; C-2, Santa Cruz Biotechnology), poly(ADP-
ribose) polymerase (PARP; 1:1,400; 6639GR, PharMingen),
and h-actin (1:10,000; AC-15, Sigma-Aldrich), followed
by incubation with alkaline phosphatase–conjugated goat
anti-mouse immunoglobulin G (1:20,000; Jackson Immu-
noResearch Laboratories). Detection of antibody-protein
complexes was done using the chemoluminescence
CDP-star (Tropix). Western blot analyses were done on
at least two independent sets of lysates with similar
results.
Measurement of Cathepsin and B-N-Acetyl-Glucosa-
minidaseActivity
Measurement of cytosolic cysteine cathepsin and h-N-
acetyl-glucosaminidase (NAG) activities was done as
previously described (28). Briefly, cell medium was
removed and extraction buffer containing 250 mmol/L
sucrose, 20 mmol/L HEPES (pH 7.5), 10 mmol/L KCl,
1.5 mmol/L MgCl2, 1 mmol/L EGTA, 1 mmol/L EDTA,
8 mmol/L DTT, and 1 mmol/L Pefabloc (Roche), supplied
with either 13.5 Ag/mL digitonin (for extraction of
cytoplasmic proteins) or 200 Ag/mL digitonin (for total
protein extraction), was added to the cells. Protein
extraction was done on ice for 10 min. Cysteine cathepsin
activity tests of extracts were done in cathepsin reaction
buffer (50 mmol/L sodium acetate, 4 mmol/L EDTA,
8 mmol/L DTT, 1 mmol/L Pefabloc, pH 6.0) by measuring
liberation of 7-amino-4-trifluoromethylcoumarin (AFC)
from the cathepsin B and L substrate zFR-AFC (50 Amol/
L; MP Biomedicals) for 20 min at 30jC with a Spectramax
Gemini fluorometer (Molecular Devices Ltd.). NAG activity
was measured by incubating extracts for 30 min with
300 Ag/mL 4-methylumbelliferyl-2-acetamido-2-deoxy-h-
D-glucopyranoside (Sigma-Aldrich) in buffer containing
0.2 mol/L sodium citrate (pH 4.5). Endpoint liberation of
methylumbelliferyl was measured with the Spectramax
Gemini fluorometer.
All cysteine cathepsin and NAG activities were normal-
ized to the activity of the cytosolic protein lactate
dehydrogenase of the same extracts to account for
variations in cell number between samples. Incubation
time and the digitonin concentration for cytoplasmic
extraction were optimized to result in total release of
cytosolic lactate dehydrogenase without release of lyso-
somal proteins. Lactate dehydrogenase activity was mea-
sured using the Cytotoxicity Detection Kit (Roche). Three
independent experiments were done with reproducible
results. In each experiment, samples were done in
triplicate.
Transfections
Plasmids pCEP4-BCL-2, pCEP4-BCL-nt, and H2B-
pEGFP-N1 were kindly provided by Marja Ja¨a¨ttela¨ (Danish
Cancer Society, Copenhagen, Denmark). pCEP4-Bcl-nt
plasmid DNA contains a nonfunctional Bcl-2 coding region
with a stop codon insertion after amino acid 218 as
previously described (29). H2B-pEGFP-N1 is encoding a
fusion-protein of histone 2B (H2B) and enhanced green
fluorescence protein (eGFP) as described before (30).
Cotransfections with H2B-pEGFP-N1/pCEP4-BCL-2 (1:4)
or H2B-pEGFP-N1/pCEP4-BCL-nt (1:4) were done with
FuGENE 6 transfection reagent (Roche) according to the
manufacturer’s instructions. Transfections were done at
least thrice with similar results.
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Flow Cytometry
Cells were incubated for 15 min with 0.5 Amol/L SYTOX
green nucleic acid stain (Invitrogen) or 2 Ag/mL propi-
dium iodide (Sigma-Aldrich), harvested by trypsinization,
and combined with floating cells from the medium. The
cells were resuspended in PBS containing 1% fetal bovine
serum. The fraction of SYTOX green– or propidium
iodide–positive cells was measured using a FACSCalibur
(Becton Dickinson) flow cytometer. Both SYTOX green
and propidium iodide are nucleic acid stains that detect
dead cells with disrupted plasma membrane and it was
tested that both staining methods gave similar results.
This allowed measurement of cell death (propidium
iodide; red) together with GFP expression (green) using
two-color settings. For SYTOX green measurements, 10,000
cells were analyzed using the FL-1 filter for determination
of the fraction of SYTOX-positive cells. For propidium
iodide measurements, 10,000 GFP-expressing cells were
gated using the FL-1 filter, and these cells were measured
at the FL-2 channel for determination of propidium
iodide–positive cells. Compensation was done to elimi-
nate overlap between the propidium iodide and GFP
emissions. In all cases, the acquired data were analyzed
using the Cell Quest Pro software. Fluorescence-activated
cell sorting analyses were done thrice with reproducible
results.
Statistical Analysis
To analyze data from crystal violet staining (cell number
determination), the two-tailed t test was used for compar-
ing mean values. For fluorescence-activated cell sorting
data, m2 analysis was done for comparing the number of
dead cells (SYTOX green or propidium iodide positive)
versus the number of live cells (SYTOX green or propidium
iodide negative). Statistical significance was concluded
when P < 0.05.
Results
Cisplatin Is More Efficient in Killing Antiestrogen-
ResistantCell Lines ThanParentalAntiestrogen-Sensitive
MCF-7 Cells
Antiestrogen-resistant MCF-7 human breast cancer cells
were treated with cisplatin for 24 h to determine their
response to cisplatin in comparison with MCF-7 cells. The
cytotoxicity of cisplatin was measured in dose-response
experiments using parental MCF-7 cells and eight different
antiestrogen-resistant cell lines. Cisplatin at a concentration
of 20 Amol/L did not result in cytotoxicity of MCF-7 cells
but resulted in f40% reduction in cell number in all eight
antiestrogen-resistant cell lines. The same pattern was seen
when treating cells with 40 and 60 Amol/L cisplatin,
respectively (i.e., cisplatin was more toxic in the anti-
estrogen-resistant cell lines than in parental MCF-7 cells).
The difference in cisplatin effect was statistically significant
(P < 0.05) in seven of the eight antiestrogen-resistant cell
lines (Fig. 1). However, when comparing LC50 values of
cisplatin treatment, 1.5- to 2.7-fold differences between
antiestrogen-resistant cells and MCF-7 cells were observed
(Table 1), showing that all antiestrogen-resistant cell lines
were indeed more sensitive to cisplatin treatment than
MCF-7 cells (P < 0.05). Withdrawal of antiestrogens 1 week
before cisplatin treatment did not change the effect of
cisplatin on the antiestrogen-resistant cell lines (data not
shown), showing that it was not the combined effect of
cisplatin and antiestrogens in the growth medium that
makes cisplatin more cytotoxic to the resistant cells.
Figure 1. Effect of cisplatin on cell number in MCF-7 and eight
antiestrogen-resistant MCF-7 sublines. Cells were treated with the
indicated concentrations of cisplatin and cell number determination was
done 24 h after addition of cisplatin by the crystal violet staining method.
The results are expressed relative to the corresponding untreated controls.
Individual experiments (from 3 to 16 were done for each cell line) were
done in triplicate and a representative experiment is shown for each cell
line. Bars, SE. The antiestrogen-resistant cell lines were tested against
MCF-7 cells at all concentrations. The TAMR-1 cell line was significantly
more sensitive to 40 and 60 Amol/L cisplatin, and in 7 of 12 individual
experiments the TAMR-1 cell line was significantly more sensitive to
20 Amol/L cisplatin compared with MCF-7 cells. The 182R-6 cell line was
significantly more sensitive than MCF-7 to 40 and 60 Amol/L cisplatin, and
in 10 of 13 experiments the 182R-6 cell line was significantly more
sensitive to 20 Amol/L cisplatin. The 182R-1, 182R-7, 182R-9, 164R-5, and
164R-7 cell lines were significantly more sensitive to all concentrations of
cisplatin. The 164R-4 cell line was not significantly different from MCF-7 in
response to cisplatin. A statistically significant difference was concluded
when P < 0.05 (two-tailed t test).
Table 1. LC50 values for cisplatin
Cell line LC50 (FSE), Amol/L
MCF-7 55.8 F 4.5
TAMR-1 26.8 F 4.9
182R-1 21.3 F 4.2
182R-6 20.6 F 3.2
182R-7 24.7 F 2.3
182R-9 30.5 F 3.8
164R-4 35.7 F 2.8
164R-5 27.5 F 0.7
164R-7 31.9 F 1.3
NOTE: For each experiment, the LC50 value (lethal concentration resulting in
50% reduction of cells) after treatment with cisplatin for 24 h was calculated
with ProStat software (Logit Model). The average LC50 values F SE are
shown. All antiestrogen-resistant cell lines have significantly different LC50
values than MCF-7 (P < 0.05, two-tailed t test).
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To ensure that dose-response curves reflected active cell
killing, flow cytometry was conducted for measuring dead
cells (SYTOX green–positive cells) after cisplatin treatment.
For this and the following experiments, two representative
and well-characterized antiestrogen-resistant cell lines
were chosen: a tamoxifen-resistant cell line, MCF-7/
TAMR-1 (TAMR-1), and an ICI 182,780–resistant cell line,
MCF-7/182R-6 (182R-6). Figure 2 shows the fraction of dead
cells measured by flow cytometry when treating MCF-7,
TAMR-1, and 182R-6 with 40 Amol/L cisplatin. In the case of
MCF-7 cells, only 7% cell death was seen after 24 h of
cisplatin treatment, and this number increased to 30% after
2 days (Fig. 2). In contrast, almost 30% of the TAMR-1 cells
were killed already after 24 h of cisplatin treatment and the
fraction of dead cells increased to 57% and 70% after 36 and
48 h, respectively. 182R-6 cells were killed even faster than
TAMR-1 cells by cisplatin; the majority of 182R-6 cells were
dead after 24 h, and after 36 h, almost all cells were killed
(Fig. 2). These results show that the antiestrogen-resistant
cells were killed more efficiently by cisplatin treatment
than the parental MCF-7 cells.
Involvement of Both Caspases and Lysosomal Pro-
teases in Cisplatin-Induced Cell Death
The broad-range caspase inhibitor zVAD-fmk and the
cysteine cathepsin inhibitor zFA-fmk were used to inves-
tigate the involvement of caspases and cysteine cathepsins
in cisplatin-induced cell death. The cytotoxicity of cisplatin
was significantly reduced when treating the cells with
zVAD-fmk or zFA-fmk together with cisplatin (Fig. 3A).
Combining both inhibitors did not result in further rescue
of cells from the cytotoxic effect of cisplatin than obtained
with zFA-fmk alone (data not shown). Cell death measured
by flow cytometry of SYTOX-stained cells confirmed that
zVAD-fmk and zFA-fmk partially rescued the cytotoxic
effects of cisplatin on the cells (Fig. 3B).
Western blot analysis of the caspase-3/caspase-7 sub-
strate PARP showed that cisplatin at concentrations up to
60 Amol/L induced cleavage of full-length PARP in TAMR-
1 and 182R-6 cells but not in MCF-7 cells (Fig. 4A). PARP
cleavage was also induced by cisplatin treatment in the
antiestrogen-resistant cell lines 182R-7, 182R-9, 164R-5, and
164R-7 (data not shown). Because MCF-7 cells are lacking
caspase-3 (31), we further investigated the involvement of
caspases in the PARP cleavage. Western blot analysis of the
PARP protein showed that cleavage was inhibited by the
caspase inhibitor zVAD-fmk, presumably through inhibi-
tion of caspase-7 activity (Fig. 4B). Surprisingly, PARP
cleavage was also inhibited by the cysteine cathepsin
inhibitor zFA-fmk (Fig. 4B). This, together with the results
showing that both zVAD-fmk and zFA-fmk could partially
rescue cells from the cytotoxic effect of cisplatin, suggests
that the mitochondrial and lysosomal death pathways act
in combination to kill the antiestrogen-resistant cells by
cisplatin.
To confirm that lysosome membrane permeabilization
was induced by cisplatin, release of lysosomal proteins to
the cytosol of MCF-7, TAMR-1, and 182R-6 was measured.
Treatment with 40 Amol/L cisplatin resulted in increased
Figure 2. Cisplatin induces increased cell death in TAMR-1 and 182R-6 cells compared with MCF-7 cells. MCF-7, TAMR-1, and 182R-6 cells were treated
with 40 Amol/L cisplatin, and SYTOX-positive cells (dead cells) were identified by flow cytometry after 24, 36, and 48 h of treatment. Three individual
experiments were done and data from one representative experiment are shown. The peaks corresponding to the dead cells are indicated in the figure and
average values of percent dead cells from all three experiments are given.
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cysteine protease cathepsin B and L and NAG activities
in the cytoplasm of the antiestrogen-resistant cell lines
compared with the parental MCF-7 cells (Fig. 4C and D).
These experiments indicate an important role of lysosomal
cysteine proteases in mediating cisplatin cell killing of the
resistant breast cancer cells.
Decreased Bcl-2 Level in Antiestrogen-Resistant Cell
Lines Is Associatedwith Increased Cisplatin Sensitivity
It has previously been shown that Bcl-2 protein expres-
sion is lower in the majority of antiestrogen-resistant
MCF-7 cell lines compared with parental MCF-7 cells
(32, 33). Figure 5A shows that the Bcl-2 protein level was
lower in all eight antiestrogen-resistant cell lines investi-
gated here compared with the MCF-7 cell line.
Therefore, we investigated whether ectopic reexpression
of Bcl-2 could reduce the cisplatin-induced cell death in
antiestrogen-resistant TAMR-1 and 182R-6 cells. MCF-7 cells
were not included in the experiment because we had
already shown that cisplatin treatment (24 h) only induced
a minimum of cell death in these cells (Figs. 2 and 3B). As a
control, we used a plasmid encoding a nonfunctional
truncated version of Bcl-2, BCL-nt (no tail), which lacks its
hydrophobic membrane-anchoring tail thereby preventing
its antiapoptotic function (29).
Expression of the two Bcl-2 constructs in TAMR-1 and
182R-6 cells was verified by Western blot analysis (Fig. 5B).
Because the transfection efficiency was quite low (5–20%;
data not shown), cotransfection was done with the Bcl-2
constructs and a H2B-eGFP plasmid. Hereby, the trans-
fected cells could be identified by flow cytometry. Cell
death of TAMR-1 and 182R-6 cells, expressing either wild-
type Bcl-2 or the nonfunctional Bcl-2 control, was
measured by identification of the fraction of propidium
iodide–positive cells among the eGFP-positive cells (Fig. 5C
and D). Treatment of antiestrogen-resistant cells in the
presence of the nonfunctional Bcl-2 led to induction of
cell death by cisplatin; at 40 Amol/L cisplatin, 26% of
TAMR-1 cells (Fig. 5C) and 81% 182R-6 cells (Fig. 5D)
were dead. This is comparable with the results from Fig. 2
(29% and 78%, respectively) showing that expression of
the nonfunctional Bcl-2 does not alter the response to
cisplatin.
Expression of full-length Bcl-2 partially rescued anties-
trogen-resistant cells from cisplatin-induced cell death. In
the case of TAMR-1 cells, the ectopic expression of Bcl-2
protein reduced cisplatin-induced cell death by f45%
(Fig. 5C), and for the 182R-6 cells, Bcl-2 reduced cell death
by f35% (Fig. 5D) irrespectively of the cisplatin concen-
tration. Statistically significant differences between trans-
fection with nonfunctional and functional Bcl-2 were
shown for all concentrations of cisplatin (20, 40, and
60 Amol/L) for both cell lines. As seen in Fig. 5D, a small
but statistically significant difference was also found
between 182R-6 cells transfected with BCL-nt and BCL-2
even without cisplatin treatment, whereas this was not the
case for TAMR-1 cells (Fig. 5C). Because 182R-6 cells were
Figure 3. Caspase and cathepsin inhibitors protect MCF-7, TAMR-1, and 182R-6 cells from cisplatin-induced cell death. A, cells were treated with the
indicated concentrations of cisplatin and 5 Amol/L zVAD-fmk or 85 Amol/L zFA-fmk. Cell number determination by the crystal violet staining method was
done after 24 h of treatment. The results are expressed relative to the corresponding controls (untreated, zVAD-fmk, or zFA-fmk alone). Four individual
experiments were done in triplicate and a representative experiment is shown for each cell line. Bars, SE. For each cell line, significant differences were
tested for cisplatin versus cisplatin combined with zFA-fmk or zVAD-fmk; *, P < 0.05, significant protection from cisplatin. B, induction of cell death was
analyzed by adding 40 Amol/L cisplatin together with 5 Amol/L zVAD-fmk or 85 Amol/L zFA-fmk. The fraction of dead cells was measured by fluorescence-
activated cell sorting analysis of SYTOX-positive cells after 24, 36, and 48 h of treatment as described in the legend of Fig. 2. The inhibitors protected
significantly (P < 0.05) against cisplatin-induced cell death at all concentrations of cisplatin in MCF-7, TAMR-1, and 182R-6 cells.
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more sensitive to the transfection procedure than TAMR-1
cells, f20% of the 182R-6 cells were dead even without
cisplatin treatment (Fig. 5D); reexpression of Bcl-2 seemed
to protect partly against this effect.
These results clearly show that Bcl-2 is expressed at a
reduced level in the antiestrogen-resistant MCF-7 sublines
and that reexpression of Bcl-2 can protect against cisplatin-
induced cell death in TAMR-1 and 182R-6 cells. This
suggests that the low expression of Bcl-2 in the anties-
trogen-resistant cells plays a significant role in determining
the sensitivity towards cisplatin.
Discussion
The data presented in this work show that breast cancer
cells with acquired resistance to antiestrogen treatment
can be killed efficiently with the platinum compound
cisplatin, in fact even more effective than the cells from
which they were subcloned. This indicates that some of
the genetic alterations associated with the development
of antiestrogen resistance in these cells eventually make
them more prone to cell death induced by cisplatin and
possibly also other compounds. In support of this, pre-
vious investigations of the antiestrogen-resistant cell lines
TAMR-1 and 182R-6 showed an increased sensitivity to
treatment with the vitamin D analogue EB1089 (32). Fur-
thermore, antiestrogen-resistant cells were shown to be
more sensitive to the phosphatidylinositol 3-kinase inhib-
itor wortmannin and the Akt inhibitor SH-6, as compared
with MCF-7 cells (11).
DNA damage–induced cell death is a complex process
involving several signaling pathways and organelles. The
data presented here indicate that cisplatin-induced cell
death of MCF-7 cells and their antiestrogen-resistant
derivatives is dependent on lysosomal cathepsin release
as well as activation of caspases. The mitochondrial
and lysosomal death pathways are not mutually exclusive
and can positively regulate each other (23, 28, 34).
Camptothecin, a DNA topoisomerase I inhibitor, induces
both lysosomal and mitochondrial membrane rupture in
lymphoma cells, and it was found that lysosomal rupture
is dependent, at least in part, on mitochondrial permeabi-
lization (35). Similarly, overexpression of Bcl-2 in immor-
talized fibroblasts effectively inhibits etoposide (a DNA
topoisomerase II inhibitor)-induced lysosomal permeabili-
zation (34). Conversely, lysosomal permeabilization in-
duced by quinolone antibiotics induces cell death that
is dependent on mitochondrial membrane permeabiliza-
tion (23). In line with these previous observations, we
show that the cysteine cathepsin inhibitor zFA-fmk
completely inhibits cisplatin-induced cleavage of the
effector caspase substrate PARP, indicating that cysteine
cathepsin activity is needed for the activation of cas-
pases. Conversely, the decreased level of Bcl-2 in the
antiestrogen-resistant cell lines compared with MCF-7 cells
correlated with a marked increase in the lysosomal
permeabilization (and cell death) induced by cisplatin.
This suggests that Bcl-2, through its inhibition of the mito-
chondrial membrane permeabilization, also prevents lyso-
somal permeabilization. Alternatively, Bcl-2 might protect
against lysosomal rupture in a more direct manner. It has
been shown that oxidative stress–induced phospholipase
Figure 4. Cisplatin induces PARP cleavage and release of lysosomal
proteins to the cytosol of TAMR-1 and 182R-6 cells. Cells were treated for
24 h with 20, 40, and 60 Amol/L of cisplatin (A) or with 40 Amol/L of
cisplatin in combination with 5 Amol/L zVAD-fmk or 85 Amol/L zFA-fmk (B).
Cells were harvested and whole-cell lysates were used for Western blot
analysis of PARP cleavage. Full-length PARP (116 kDa) and the
85-kDa PARP cleavage product are indicated. Detection of h-actin protein
was used as control for equal loading. Cells were treated with 40 Amol/L
cisplatin and activities of the lysosomal proteins, cysteine cathepsins
(CathB/L ; C) and NAG (D), were measured after 12, 18, and 24 h. Total
and cytosolic activities were measured and normalized to the lactate
dehydrogenase activity of the same sample. Activities are expressed as
cytosolic activity in percentage of the total activity. Three independent
experiments were done in triplicate with similar results and one represen-
tative experiment is shown. *, P < 0.05, compared with MCF-7. Bars, SE.
Cisplatin and Antiestrogen-Resistant Cell Lines1874
Mol Cancer Ther 2007;6(6). June 2007
A2 activation, which is associated with destabilization
of both mitochondrial and lysosomal membranes, is
inhibited by Bcl-2 overexpression in murine lymphoma
J774 cells (36, 37). Due to its ability to inhibit both death
pathways, Bcl-2 would be expected to play an important
role in determining the outcome of cisplatin treatment
of antiestrogen-resistant breast cancer cells. Indeed, over-
expression of wild-type Bcl-2, but not the nonfunctional
truncated version, significantly reduced the cisplatin
sensitivity of two different antiestrogen-resistant cell lines.
The positive coregulation between two death-promoting
signaling pathways, as described above, may help to
ensure that once a cell has activated either pathway above
a certain threshold (here due to DNA damage), the death
signal is amplified to ensure that the cell is effectively
eradicated. A similar positive feedback mechanism has
recently been described for activated effector caspases that
feedback to enhance mitochondrial membrane permeabili-
zation and thereby the release of proapoptotic factors from
the mitochondria (38).
Clinical trials with the platinum compound carboplatin
in combination therapy for metastatic breast cancer are
ongoing and thus far show promising results (39),
indicating the potency of using platinum compounds
for treating breast cancer. To our knowledge, studies of
the effect of cisplatin in antiestrogen-resistant patients
have not yet been conducted. However, our data imply
that breast cancer patients who have relapsed on anties-
trogen treatment might be good responders to cisplatin
and that low Bcl-2 expression could be used as a pre-
dictive marker. This gives hope to the future treatment of
breast cancer patients with acquired antiestrogen resis-
tance.
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